Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBOC-201 in Elective PCI
NCT00479895Phase 2Completed
- Sponsor
- Biopure
- Start
- Apr 2007
- Primary completion
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hemoglobin glutamer-250 in Myocardial ischemia (MI) (2 arms), sponsored by Biopure. Primary endpoints: Change in left ventricular relaxation indices, Change in pressure-half time and 1 more. Started Apr 2007; status: completed.
02
Drugs
hemoglobin glutamer-250
03
Conditions
Myocardial ischemia (MI)
Beyond the preview
Go deeper on NCT00479895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00479895.